Log In
Print this Print this

icrucumab (IMC-18F1, LY3012212)

  Manage Alerts
Collapse Summary General Information
Company Eli Lilly and Co.
DescriptionHuman IgG1 mAb against vascular endothelial growth factor receptor-1 (VEGFR1)
Molecular Target Vascular endothelial growth factor (VEGF) receptor 1 (FLT1) (VEGFR-1)
Mechanism of ActionVascular endothelial growth factor (VEGF) inhibitor; Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today